Gilead Sciences
Pays vs peer median
×1.42
+42% premium
Sample
34
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.41 | 24 |
| immunology | ×1.04 | 3 |
| gastroenterology | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.50 | 9 |
| phase 3 | ×1.50 | 7 |
| phase 1 | ×0.98 | 6 |
| phase 2 | ×1.50 | 6 |
| preclinical | ×0.98 | 6 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | KT-200 | Kymera Therapeutics | breast cancer | preclinical | $45M | $710M |
| 2026 | ADC pipeline | Tubulis | oncology | unknown | $3.1B | $3.1B |
| 2026 | — | Tubulis GmbH | ovarian cancer, non-small cell lung cancer | phase_2 | $3.1B | $5.0B |
| 2026 | TUB-040 | Tubulis | platinum-resistant ovarian cancer, non-small cell lung cancer | phase_2 | $3.1B | $5.0B |
| 2026 | BCMAxCD3 T-cell engager | Ouro Medicines | severe autoimmune diseases | unknown | $1.7B | $2.2B |
| 2026 | OM336 (gamgertamig) | Ouro Medicines | autoimmune_diseases | phase_1 | $1.7B | $2.2B |
| 2026 | GH31 | Genhouse Bio | solid_tumor | phase_1 | $80M | $1.5B |
| 2026 | — | Genhouse Bio Co. Ltd. | solid_tumor | phase_1 | — | $1.5B |
| 2026 | SMN-101 | Cassava Sciences | Major Depressive Disorder | phase_1 | $98M | $1.2B |
| 2026 | DLL3-001 | Syros Pharmaceuticals | Colorectal | preclinical | $157M | $1.2B |
| 2025 | ABI-5366 + ABI-1179 (HSV) | Assembly Biosciences | Recurrent genital herpes (HSV-2) | phase_1 | $35M | $365M |
| 2025 | Anti-TIM-3-mab | Hengrui Medicine | ALL | phase_1 | — | $1.0B |
| 2025 | Anti-FLT3-301 | Umoja Biopharma | NSCLC | phase_2 | $315M | $3.4B |
| 2025 | CD22-101 | BioNTech | Melanoma | phase_3 | $650M | $4.0B |
| 2025 | Anti-ICOS-001 | Denali Therapeutics | SCLC | phase_1 | $105M | $1.2B |
How this is computed
For each Gilead Sciences deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 34 disclosed deal premiums vs. peer medians. Raw premium 1.421, clamped to [0.7, 1.5].